Pharmacotherapy in Parkinson’s disease.
Pharmacotherapy in Parkinson’s disease is complex, with dopaminergic stimulation as its backbone. During the past decade only a few new drugs have been registered. However, progress has been made in clinical experience. Recent studies suggest better and longer efficacy of MAO-B inhibitors. Therapy of advanced stages of Parkinson’s disease remains a challenge as the therapeutic window narrows and motor complications prevail.